Lebanon

Population 2013   **4.8 million**

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.042 (0.012–0.092)	0.86 (0.24–1.9)
Mortality (HIV+TB only)	0 (–)	0 (–)
Prevalence (includes HIV+TB)	0.9 (0.32–1.8)	19 (6.7–37)
Incidence (includes HIV+TB)	0.76 (0.66–0.86)	16 (14–18)
Incidence (HIV+TB only)		
Case detection, all forms (%)	91 (80–110)	

(Rate per 100 000 population per year)

Mortality (excludes HIV+TB)

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	1.1 (0.1–3.8)	29 (3.7–71)
MDR-TB cases among notified pulmonary TB cases	4 (0–15)	2 (0–6)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	248	8
Pulmonary, clinically diagnosed	142	0
Extrapulmonary	291	0
Total new and relapse	**689**	
Previously treated, excluding relapses	0	
Total cases notified	**689**	

Among 681 new cases:
52 (8%) cases aged under 15 years; male:female ratio: 0.7

(Rate per 100 000 population)

Prevalence

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB	23 (9%)	7 (88%)	30
Laboratory-confirmed RR-/MDR-TB cases			10
Patients started on MDR-TB treatment			8

TB/HIV 2013	Number	(%)
TB patients with known HIV status	354	(51)
HIV-positive TB patients	5	(1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	5	(100)
HIV-positive TB patients on antiretroviral therapy (ART)	5	(100)
HIV-positive people screened for TB	102	
HIV-positive people provided with IPT	50	

(Rate per 100 000 population per year)

Notified (new and relapse)   Incidence
Incidence (HIV+TB only)

| Treatment success rate	(%)
New and relapse cases registered in 2012	71
Previously treated cases, excluding relapse, registered in 2012	
HIV-positive TB cases, all types, registered in 2012	0
RR-/MDR-TB cases started on second-line treatment in 2011	100
XDR-TB cases started on second-line treatment in 2011	

(Number of patients)

HIV-positive TB patients
on CPT   on ART

Laboratories 2013	
Smear (per 100 000 population)	3.7
Culture (per 5 million population)	20.7
Drug susceptibility testing (per 5 million population)	1.0
Sites performing Xpert MTB/RIF	0
Is second-line drug susceptibility testing available?	Yes, outside country

Treatment success rate (%)

New   Retreatment
New and relapse   Retreatment, excluding relapse
HIV-positive   RR-/MDR-TB   XDR-TB

Financing TB control 2014	
National TB programme budget (US$ millions)	<1
% Funded domestically	91%
% Funded internationally	0%
% Unfunded	9%

Total budget (US$ millions)

Funded domestically   Funded internationally
Unfunded

Ranges represent uncertainty intervals
** *Includes cases with unknown previous TB treatment history*